Of these, mesothelin over-expression in triple-negative breast cancer (TNBC) was of primary interest to us (28, 29), given (i) the CAF rich TME that correlates with poor prognosis (30, 31), and (ii) the urgent need for development of new therapies due to current lack of targeted and effective treatment options. The gene discussed is MSLN; the disease is triple-negative breast carcinoma.